PT - JOURNAL ARTICLE AU - Jordy Dekker AU - Rachel Schot AU - Michiel Bongaerts AU - Walter G. de Valk AU - Monique M. van Veghel-Plandsoen AU - Kathryn Monfils AU - Hannie Douben AU - Peter Elfferich AU - Esmee Kasteleijn AU - Leontine M.A. van Unen AU - Geert Geeven AU - Jasper J. Saris AU - Yvette van Ierland AU - Frans W. Verheijen AU - Marianne L.T. van der Sterre AU - Farah Sadeghi Niaraki AU - Hidde H. Huidekoper AU - Monique Williams AU - Martina Wilke AU - Virginie J.M. Verhoeven AU - Marieke Joosten AU - Anneke J.A. Kievit AU - Ingrid M.B.H. van de Laar AU - Lies H. Hoefsloot AU - Marianne Hoogeveen-Westerveld AU - Mark Nellist AU - Grazia M.S. Mancini AU - Tjakko J. van Ham TI - RNA-sequencing improves diagnosis for neurodevelopmental disorders by identifying pathogenic non-coding variants and reinterpretation of coding variants AID - 10.1101/2022.06.05.22275956 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.05.22275956 4099 - http://medrxiv.org/content/early/2022/06/07/2022.06.05.22275956.short 4100 - http://medrxiv.org/content/early/2022/06/07/2022.06.05.22275956.full AB - Background For neurodevelopmental disorders (NDD), a molecular diagnosis is key for predicting outcome, treatment and genetic counseling. Currently, in about half of NDD cases, routine DNA-based testing fails to establish a genetic diagnosis. Transcriptome analysis (RNA-seq) improves the diagnostic yield for some groups of diseases, but has not been applied to NDD in a routine diagnostic setting.Methods Here, we explored the diagnostic potential of RNA-seq in a cohort of 96 individuals including 67 undiagnosed NDD subjects. We created a user-friendly web-application to analyze RNA-seq data from single individuals’ cultured skin fibroblasts for genic, exonic and intronic expression outliers, based on modified OUTRIDER Z-scores. Candidate pathogenic events were complemented/matched with genomic data and, if required, confirmed with additional functional assays.Results We identified pathogenic small genomic deletions, mono-allelic expression, aberrant splicing events, deep intronic variants resulting in pseudo-exon insertion, but also synonymous and nonsynonymous variants with deleterious effects on transcription. This approach increased the diagnostic yield for NDD by 12%. Diagnostic pitfalls during transcriptome analysis include detection of splice abnormalities in putative disease genes caused by benign polymorphisms and/or absence of expression of the responsible gene in the tissue of choice. This was misleading in one case and could have led to the wrong diagnosis in the absence of appropriate phenotyping.Conclusions Nonetheless, our results demonstrate the utility of RNA-seq in molecular diagnostics and stress the importance of multidisciplinary team consultation. In particular, the approach is useful for the identification and interpretation of unexpected pathogenic changes in mRNA processing and expression in NDD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTJvH was funded by an Erasmus University Rotterdam (EUR) fellowshipAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Erasmus MC gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors (IRB protocol METC-2012-387)